1. Home
  2. Live Updates
  3. Martinaj porter

Live Breaking News & Updates on Martinaj porter

Stay informed with the latest breaking news from Martinaj porter on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Martinaj porter and stay connected to the pulse of your community

Ruxolitinib Cream Shows Promise for Hidradenitis Suppurativa

Treatment with the topical JAK inhibitor reduced abscess and inflammatory nodules in a phase 2 randomized, controlled trial in patients with mild hidradenitis suppurativa.

United-states , California , University-of-southern-california , Boston , Massachusetts , American , Martinaj-porter , P-jenniferl-hsiao , Los-angeles , Beth-israel-deaconess-medical-center , Harvard-medical-school , American-academy-of-dermatology

A New Study Finds That Ruxolitinib Cream 1.5% Is Effective for Most Patients With HS

The cream significantly reduced abscesses and inflammatory nodules, reaffirming its efficacy as a maintenance option for HS.

California , United-states , San-diego , American , Martinaj-porter , Jim-lee , Dmytro-flisak , Beth-israel-deaconess-medical-center , International-hidradenitis-suppurativa-severity-score-system , American-academy-of-dermatology , American-academy , Beth-israel-deaconess-medical

Late-Breaking Abstracts Highlight Promising Therapies in AD, Hidradenitis Suppurativa

Experts at the American Academy of Dermatology Annual Meeting shared results of research into various topical and systemic therapies for atopic dermatitis (AD) and hidradenitis suppurativa during a late-breaking abstract session.

United-states , Ireland , Dublin , San-diego , California , American , Brian-kirby , Jonathani-silverberg , Lawrencef-eichenfield , Jills-waibel , Eli-lilly , Martinaj-porter

Incyte reports promising results in Phase 2 test of Opzelura cream

Incyte reports promising results in Phase 2 test of Opzelura cream
delawarebusinessnow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from delawarebusinessnow.com Daily Mail and Mail on Sunday newspapers.

United-states , American , Martinaj-porter , Beth-israel-deaconess-medical-center , Us-food-drug-administration , American-academy-of-dermatology-annual-meeting , American-academy , Dermatology-annual , Beth-israel-deaconess-medical , Drug-administration ,

Martina J. Porter, MD: New Findings on Efficacy, Safety of Ruxolitinib Cream Among Patients with HS

Martina J. Porter, MD: New Findings on Efficacy, Safety of Ruxolitinib Cream Among Patients with HS
hcplive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hcplive.com Daily Mail and Mail on Sunday newspapers.

United-states , San-diego , California , American , Martinaj-porter , Harvard-medical-school , American-academy-of-dermatology , Harvard-medical ,

Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa

Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states , Ohio , San-diego , California , America , American , Jim-lee , Martinaj-porter , Hidradenitis-suppurativa , Rare-diseases-information-center , Group-vice , Youtube

Martina J. Porter, MD: Adverse Events, Future Research on Lutikizumab for HS

In this segment of Porter’s interview, she delves further into the phase 2 findings on lutikizumab and discusses any adverse events and future research.


Martinaj-porter , Harvard-medical-school , Hs , Hidradenitis-suppurativa , Lutikizumab , Dermatology , Porter ,

Martina J. Porter, MD: Discussing New Findings on Lutikizumab for HS Patients

In this interview, Porter describes some new and encouraging phase 2 data on lutikizumab treatment for patients with HS who had failed anti-TNF therapy.


Martinaj-porter , Harvard-medical-school , Beth-israel-deaconess-medical-center , Hs , Hidradenitis-suppurativa , Lutikizumab , Interview , Porter ,